Support and Resistance Levels
Past performance
About Smruthi Organics Ltd Smruthi Organics Limited, established in 1989 and transitioned to a public entity in 1995, specializes in manufacturing Active Pharmaceutical Ingredients (API) within therapeutic categories such as Anti-Diabetic, Anti-Hypertension, and Anti-Infectives. The company serves both the Indian market and international clients across Asia, Americas, and Africa. Operating from two manufacturing facilities in Solapur, India, Smruthi Organics initially focused on bulk drugs like diloxanide furoate and sulphadiazine, later expanding to include metronidazole benzoate, tinidazole, paracetamol, and norfloxacin.
The company has continually expanded its product range, proposing an additional plant in Maharashtra for ciprofloxacin and ranitidine HCl in 1995 and commercializing an expansion project in 2012. In 2021, its Finished Dosage Formulations Division became fully operational, and in FY 2022-23, Smruthi Organics launched new brands 'ENERLIN' and 'SOLSITA', illustrating its commitment to growth and innovation in the pharmaceutical sector.